Affordable Access

deepdyve-link
Publisher Website

Antibody response to the first dose of AZD1222 vaccine in COVID-19 convalescent and uninfected individuals in Bangladesh

Authors
  • Jamiruddin, Raeed1, 2
  • Haq, Ahsanul2
  • Khondoker, Mohib Ullah2, 3
  • Ali, Tamanna2
  • Ahmed, Firoz Md.4
  • Khandker, Shahad Saif2
  • Jawad, Irfan4
  • Hossain, Rubel5
  • Ahmed, Sohel4
  • Rahman, Sabita Rezwana6
  • Mustafi, Mamun3
  • Kaitsuka, Taku7
  • Mie, Masayasu8
  • Tomizawa, Kazuhito9
  • Kobatake, Eiry8
  • Haque, Mainul10
  • Adnan, Nihad2, 4
  • 1 Brac University, Bangladesh , (Bangladesh)
  • 2 Gonoshasthaya-RNA Molecular Diagnostic & Research Center, Bangladesh , (Bangladesh)
  • 3 Gonoshasthaya Samaj Vittik Medical College, Bangladesh , (Bangladesh)
  • 4 Jahangirnagar University, Bangladesh , (Bangladesh)
  • 5 Gono Bishwabidyalay, Bangladesh , (Bangladesh)
  • 6 University of Dhaka, Bangladesh , (Bangladesh)
  • 7 School of Pharmacy, International University of Health and Welfare, Japan , (Japan)
  • 8 Tokyo Institute of Technology, Japan , (Japan)
  • 9 Graduate School of Medical Sciences, Kumamoto University, Japan , (Japan)
  • 10 Nasional Malaysia (National Defence University of Malaysia), Kem Perdana Sugai Besi, Malaysia , (Malaysia)
Type
Published Article
Journal
Expert Review of Vaccines
Publisher
Informa UK (Taylor & Francis)
Publication Date
Sep 15, 2021
Pages
1–10
Identifiers
DOI: 10.1080/14760584.2021.1977630
PMID: 34503369
PMCID: PMC8442763
Source
PubMed Central
Keywords
Disciplines
  • Original Research
License
Unknown

Abstract

Background Vaccination with the Oxford-AstraZeneca COVID-19 vaccine (AZD1222) initially started in the UK and quickly implemented around the Globe, including Bangladesh. Up to date, more than nine million doses administrated to the Bangladeshi public. Method Herein, we studied the antibody response to the first dose of AZD1222 in 86 Bangladeshi individuals using in-house ELISA kits. Study subjects were categorized into two groups, convalescent and uninfected, based on prior infection history and SARS-CoV-2 nucleocapsid-IgG profiles. Results All the convalescent individuals presented elevated spike-1-IgG compared to 90% of uninfected ones after the first dose. Day >28 post-vaccination, the convalescent group showed six times higher antibody titer than the uninfected ones. The most elevated antibody titers for the former and later group were found at Day 14 and Days >28 post-vaccination, respectively. The spike-1-IgA titer showed a similar pattern as spike-1-IgG, although in a low-titer. In contrast, the IgM titer did not show any significant change in either group. Conclusion High antibody titer in the convalescent group, signify the importance of the first dose among the uninfected group. This study advocates the integration of antibody tests in vaccination programs in the healthcare system for maximizing benefit.

Report this publication

Statistics

Seen <100 times